|
5/16/2013 7:32:52 AM
|
Nuvo Research Says WF10 Therapeutic Data Impact On Signs And Symptoms Of Experimentally Induced Rheumatoid Arthritis
|
|
5/14/2013 5:08:40 PM
|
Nuvo Research Receives U.S. Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10
|
|
5/14/2013 5:06:54 PM
|
Nuvo Research Granted U.S. Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10
|
|
5/9/2013 7:33:51 AM
|
European Patent Office Issues Notice Of Intention To Grant European Patent To Nuvo Research's PENNSAID 2%
|
|
5/7/2013 7:36:33 AM
|
Nuvo Research To Proceed With Its Proposed Share Consolidation
|
|
5/1/2013 10:15:43 PM
|
|
|
4/23/2013 7:31:32 AM
|
Nuvo Research Unveils European Launch Of Pliaglis By Galderma
|
|
3/27/2013 5:02:03 PM
|
Nuvo Research Q4 Loss Per Share $0.020 Vs Loss $0.003 Last Year
|
|
3/11/2013 7:31:49 AM
|
Nuvo Research Announces U.S. Launch Of Pliaglis By Galderma
|
|
3/11/2013 7:31:35 AM
|
Nuvo Research Announces U.S. Launch Of Pliaglis Cream 7%/7%
|
|
3/5/2013 9:04:31 PM
|
|
|
3/5/2013 7:09:56 AM
|
|
|
3/5/2013 7:02:50 AM
|
Nuvo Research Announces FDA Response To PENNSAID 2% NDA
|
|
1/29/2013 7:35:27 AM
|
Nuvo Research Enters Into Settlement Agreement With Apotex In PENNSAID Generic Litigation
|
|
11/1/2012 7:33:05 AM
|
|
|
10/31/2012 5:20:06 PM
|
Nuvo Research Posts Q3 Loss/Share Of C$0.006 Vs. Loss C$0.004 Last Year
|
|
9/5/2012 7:32:34 AM
|
Nuvo Research Receives U.S. Patent For PENNSAID 2%
|
|
8/1/2012 5:28:05 PM
|
Nuvo Research Posts Q2 Net Income Of C$3.33 Mln Or C$0.006/Share On Revenues Of C$9.16 Mln
|
|
7/26/2012 7:31:46 AM
|
Nuvo Research Gets €4.4 Mln Addl. Funding To Develop WF10
|
|
7/25/2012 7:32:03 AM
|
Nuvo Research Unveils New Listing Of Synera Patent In FDA Orange Book
|